ANLN and hepatocellular carcinoma: In addition, as with all experimental models, this in vivo bone metastasis model may not fully reflect the disease in patients, so further verification with other models would be beneficial to substantiate both the phenotype and molecular mechanisms of the m6A-METTL3/YTHDF1-ANLN axis in driving HCC BM.